SQSTM1 and neoplasm: The response at the p62 DNA (doses of 0.75, 1.0 or 2.5 mg once a week for 3–10 weeks) was characterized by two phases: an increase in tumor size at the beginning of the administration (likely due immune cells infiltration) followed by tumor shrinkage.